QUIDELORTHO CORP (QDEL) Operating Margin
- Operating margin · 12 months: Value -30.84%; Formula and calculation Operating income / revenue. Period ending 2026-06-28..
Operating margin
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -30.84% | Operating income / revenue. Period ending 2026-06-28. $-824.70M ÷ $2.67B × 100 ≈ -30.84% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -824.70M USD | Operating Income (Loss) |
| Revenue | 2.67B USD | |
| Cost of products and services | (m) | |
| Research and development | 180.90M USD | Research and Development Expense |
| Selling, general and administration | 770.30M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-28 | $-824.70M | $2.67B | (m) | $180.90M | $770.30M | -30.84% |
| 2026-03-29 | $-983.60M | $2.66B | (m) | $177.90M | $758.60M | -37.02% |
| 2025-12-28 | $-919.20M | $2.73B | (m) | $186.20M | $746.30M | -33.67% |
| 2025-09-28 | $-953.30M | $2.71B | (m) | $187.70M | $739.40M | -35.12% |
| 2025-06-29 | $-233.50M | $2.74B | (m) | $202.10M | $738.90M | -8.52% |
| 2025-03-30 | $-170.30M | $2.76B | (m) | $212.70M | $749.10M | -6.16% |
| 2024-12-29 | $-1.96B | $2.78B | (m) | $218.70M | $766.80M | -70.46% |
| 2024-09-29 | $-1.82B | $2.82B | (m) | $232.50M | $766.90M | -64.61% |
| 2024-06-30 | $-1.81B | $2.83B | (m) | $238.10M | $774.60M | -63.82% |
| 2024-03-31 | $-1.72B | $2.86B | (m) | $243.70M | $765.50M | -60.03% |
| 2023-12-31 | $139.10M | $3.00B | (m) | $246.80M | $763.20M | 4.64% |
| 2023-10-01 | $185.50M | $3.12B | (m) | $251.80M | $789.20M | 5.94% |
| 2023-07-02 | $216.00M | $3.16B | (m) | $255.00M | $799.30M | 6.83% |
| 2023-04-02 | $322.60M | $3.11B | (m) | $226.40M | $738.60M | 10.37% |
| 2023-01-01 | $843.70M | $3.27B | (m) | $190.50M | $621.00M | 25.83% |
| 2022-10-02 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-07-03 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-04-03 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-01-02 | $906.00M | $1.70B | (m) | $95.70M | $239.60M | 53.34% |
| 2021-10-03 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-07-04 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-01-03 | $1.06B | $1.66B | (m) | $84.30M | $180.70M | 63.81% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |